Gastroenteropancreatic neuroendocrine tumours. by Modlin, I, Oberg, K, Chung, D, Jensen, RT, de Herder, W, Thakker, R, Caplin, M, Delle Fave, G, Kaltsas, G, Krenning, E, Moss, S, Nilsson, O, Rindi, G, Salazar, R, Ruszniewski, P, Sundin, A

“…They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass effects. …”

Carcinoid tumors outside the abdomen by Kenna Koehler, Wade T. Iams

“…Both bronchial and thymic carcinoids can present with symptoms of obstruction and potentially carcinoid syndrome. The gold standard of management of bronchial and thymic carcinoid tumors is surgical resection. …”
Get full text

Targeted treatment with somatostatin analogues: widening horizons of clinical practice by Vyacheslav S. Pronin, Mikhail B. Antsiferov, Tatiana M. Alexeeva, Evgeny V. Pronin

“…The anti-secretory and anti-tumor effects of SA have been proven for gastroenteropancreatic tumors (carcinoid syndrome, vipomas, gastrinomas, insulinomas, glucagonomas, somatostatinomas). …”
Get full text

Sigmoid Colon Perforation during Colonoscopy in a Case of Carcinoid Tumor by Bizhan Ahmadi, Motahareh Zaherara, Faezeh Hasani Saadi, Sara Azhdari

“…These products could cause carcinoid syndrome, and also, fibrosis in the peritoneum and mesentery.Case report: A 50-year-old man complaining of lower limb edema, ascites, and weight loss presented for evaluation. …”
Get full text

Elevated Peripheral Blood Plasma Concentrations of Tie-2 and Angiopoietin 2 in Patients with Neuroendocrine Tumors by Henryk Stepien, Hanna Lawnicka, Jan Komorowski, Ewelina Motylewska, Agata Niedziela, Slawomir Mucha, Gabriela Melen-Mucha

“…Similarly, in the subgroup of patients with carcinoid syndrome, only Tie-2 and CgA concentrations were higher than those in patients with non-functioning NETs. …”
Get full text

Conventional Transarterial Chemo embolization Using Streptozocin in Patients with Unresectable Neuroendocrine Liver Metastases by Audrey Fohlen, Remi Beaudouin, Arnaud Alvès, Karine Bouhier-Leporrier, Christophe Pasik, Jean-Pierre Pelage

“…All patients received streptozocin and Lipiodol. Carcinoid syndrome was improved in 69% of patients after treatment (<i>p</i> = 0.01). …”
Get full text

Ablation of typical atrial flutter as therapeutic component in carcinoid heart disease: a case report by Susann Groschke, Rolf Weinert, Björn Becker, Gert Richardt, Ralph Tölg, Leon Iden, Martin Borlich

“…Abstract Background Carcinoid heart disease is the cardiac manifestation of carcinoid syndrome. There is limited research on rhythm management in patients with carcinoid heart disease. …”
Get full text

Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency by Camilla Bardasi, Stefania Benatti, Gabriele Luppi, Ingrid Garajovà, Federico Piacentini, Massimo Dominici, Fabio Gelsomino

“…It is characterized by a sudden onset of hemodynamic instability, sometimes associated with the classical symptoms of carcinoid syndrome, such as bronchospasm and flushing. Carcinoid Crisis seems to be caused by a massive release of vasoactive substances, typically produced by neuroendocrine cells, and can emerge after abdominal procedures, but also spontaneously in rare instances. …”
Get full text

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin by Rendell MS

“…Lexicon successfully developed telotristat to treat carcinoid syndrome not responding adequately to somatostatin inhibitors. …”
Get full text

Multimodality Imaging of the Neglected Valve: Role of Echocardiography, Cardiac Magnetic Resonance and Cardiac Computed Tomography in Pulmonary Stenosis and Regurgitation by Pietro Costantini, Francesco Perone, Agnese Siani, Léon Groenhoff, Giuseppe Muscogiuri, Sandro Sironi, Paolo Marra, Serena Carriero, Anna Giulia Pavon, Marco Guglielmo

“…However, pulmonary regurgitation (PR) and pulmonary stenosis (PS) can occur in a variety of patients ranging from fetuses, newborns (e.g., tetralogy of Fallot) to adults (e.g., endocarditis, carcinoid syndrome, complications of operated tetralogy of Fallot). …”
Get full text

Liver transplantation in gastroenteropancreatic neuroendocrine tumors by Eduardo de Souza M. Fernandes, Eduardo de Souza M. Fernandes, Eduardo de Souza M. Fernandes, Eduardo de Souza M. Fernandes, Camila V. Garcia Kyt, Camila V. Garcia Kyt, Felipe Pedreira Tavares de Mello, Felipe Pedreira Tavares de Mello, Leandro Savattone Pimentel, Leandro Savattone Pimentel, Ronaldo de Oliveira Andrade, Ronaldo de Oliveira Andrade, Camila Girão, Camila Girão, Camilla César, Camilla César, Munique Siqueira, Munique Siqueira, Maria Eduarda Monachesi, Maria Eduarda Monachesi, Anderson Brito, Claudia Cristina Tavares de Sousa, Wellington Andraus, Orlando Jorge M. Torres, Orlando Jorge M. Torres

“…When neuroendocrine tumors present clinical and compressive symptoms, carcinoid syndrome is evident. Carcinoid syndrome occurs when the tumor produces neuroendocrine mediators that cannot be metabolized by the liver due to either the size of the tumor or their secretion by the liver itself. …”
Get full text

Treatment of idiopathic anaphylaxis with dupilumab: a case report by Elizabeth Pepper, Luke Pittman

“…Her workup at this point was negative for food allergy, alpha gal syndrome, systemic mastocytosis, hereditary alpha tryptasemia, carcinoid syndrome, and pheochromocytoma, and she was trialed on dupilumab with near resolution of her symptom frequency over a six month time period. …”
Get full text

Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns by Robert Brommage, David R. Powell, Peter Vogel

“…For example, studying Tph1 knockout mice (lacking peripheral serotonin) aided the development of telotristat ethyl, an approved treatment for carcinoid syndrome. Sglt1 (also known as Slc5a1) and Sglt2 (also known as Slc5a2) knockout mice were employed to develop sotagliflozin, a dual SGLT1/SGLT2 inhibitor having success in clinical trials for diabetes. …”
Get full text

The importance of serotonin in the gastrointestinal tract by Jarosław Koza, Renata Kwiatkowska, Adam Jurgoński, Małgorzata Pujanek, Monika Ameryk, Piotr Sikorski, Agnieszka Meder, Maciej Świątkowski

“…Serotonin is responsible for some symptoms of carcinoid syndrome. It is the result of higher 5-hydroxytryptamine content in the body. …”
Get full text

Primary Well-Differentiated Neuroendocrine Tumor of the Kidney by Vishnu Prasad, Charakkulam Vijay Sreelakshmi, K Ravi Chandran, Shashank Agrawal, Ginil Kumar Pooleri, Amrita Sao

“…High index of suspicion needs to be observed in patients presenting with carcinoid syndrome and a renal mass. Nuclear scans like PET scan and DOTANOC scan can accurately stage the disease. …”
Get full text

Neuroendocrine tumors of the vagina by S. O. Nikogosyan, T. Sh. Tagibova, O. A. Anurova, A. A. Markovich, L. I. Korolenkova, V. V. Kuznetsov

“…The paper covers the most important topographic-anatomic and histological characteristics of the vagina, gives general information on the epidemiology of primary vaginal cancer (VC), on the rules of its staging, describes the frequently encountered morphological types of this tumor, and indicates the properties and features of the course of neuroendocrine tumors (NETs), including the most common manifestations of carcinoid syndrome and the symptoms of tumor hypersecretion of a number of biologically active substances. …”
Get full text

From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours by Emilio Bajetta, Giuseppe Procopio, Sara Pusceddu, Filippo Pietrantonio, Massimo Milione, Marco Maccauro, Elena Verzoni, Valentina Guadalupi, Marco Platania

“…Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. …”
Get full text

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours? by Gupta, P, Grozinsky-Glasberg, S, Drake, WM, Akker, SA, Perry, L, Grossman, AB, Druce, MR

“…Of 46 subjects evaluated (48·9% males, 63·8 ± 10·5 years, BMI 26·6 ± 4·4 kg/m2) with 32 gastrointestinal, 9 pancreatic, 3 pulmonary and 2 ovarian NETs, 72·3% had the carcinoid syndrome. Median interval from diagnosis was 4·0 years (IQR 2·0-6·0); 41·3% had osteoporosis and 32·6% osteopaenia (WHO definition). …”

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours? by Sen Gupta, P, Grozinsky-Glasberg, S, Drake, WM, Akker, SA, Perry, L, Grossman, AB, Druce, MR

“…Of 46 subjects evaluated (48·9% males, 63·8 ± 10·5 years, BMI 26·6 ± 4·4 kg/m(2) ) with 32 gastrointestinal, 9 pancreatic, 3 pulmonary and 2 ovarian NETs, 72·3% had the carcinoid syndrome. Median interval from diagnosis was 4·0 years (IQR 2·0-6·0); 41·3% had osteoporosis and 32·6% osteopaenia (WHO definition). …”

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. by Chan, H, Grossman, AB, Bukowski, R

“…Forthcoming data from phase 3 placebo-controlled trials of everolimus, one focused on monotherapy for pancreatic NET and the other on combination use with octreotide LAR for patients with advanced NET and a history of carcinoid syndrome, will provide insight into its future place in NET therapy. …”